Commentary By Michael J. New is a research associate at the Busch School of Business at the Catholic University of America and an associate scholar at the Charlotte Lozier Institute. Pro-life advocates suffered a policy setback last week when the Food and Drug Administration lifted existing restrictions on telemedicine abortions for the duration of the COVID-19 pandemic. This past year, groups supporting legal abortion litigated against Trump administration FDA rules, which required that chemical abortions occur under medical supervision. Supporters of legal abortion obtained a favorable ruling from a U.S. district court judge in July. However, in January, the U.S. Supreme Court ruled that the Trump administration’s protective rules were constitutional and could remain in place.